医学
机会之窗
疾病
类风湿性关节炎
克罗恩病
炎症性肠病
重症监护医学
干预(咨询)
治疗窗口
内科学
英夫利昔单抗
溃疡性结肠炎
临床试验
精神科
药理学
实时计算
计算机科学
作者
Silvio Danese,Gionata Fiorino,Carlos Fernandes,Laurent Peyrin–Biroulet
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2014-09-08
卷期号:15 (11): 1056-1063
被引量:46
标识
DOI:10.2174/1389450115666140908125738
摘要
Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life. Keywords: Crohn’s disease, early disease, inflammatory bowel disease, therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI